11:41 AM EST - Stem Cell Therapeutics Corp. : said it closed patient enrollment of the modified Phase IIb stroke trial on March 31, and will analyze the data as they become available. Using a modified statistical approach the company will analyze its trial data using the 96 patients that were enrolled. With the modified Phase IIb stroke trial closed, Stem Cell Therapeutics anticipates to complete patient 90 day endpoint assessments by the end of April 2010 with data analysis to follow soon after. Stem Cell Therapeutics Corp.
shares V.SSS are trading up $0.005 at $0.30.
